Who are BioChaperone PDGF-BB's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rolvedon, Tepezza, Oxervate, Lartruvo, Citomix, Portrazza.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/biochaperone-pdgf-bb.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BioChaperone PDGF-BB — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BioChaperone PDGF-BB (BioChaperone PDGF-BB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth factor. Area: Wound Care / Regenerative Medicine.

phase 3 Growth factor PDGF receptor (PDGFR) Wound Care / Regenerative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

BioChaperone PDGF-BB (BioChaperone PDGF-BB) — Adocia. BioChaperone PDGF-BB is a formulation of platelet-derived growth factor BB designed to enhance wound healing and tissue repair by promoting angiogenesis and cell proliferation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BioChaperone PDGF-BB TARGET	BioChaperone PDGF-BB	Adocia	phase 3	Growth factor	PDGF receptor (PDGFR)
Rolvedon	EFLAPEGRASTIM	Spectrum Pharms	marketed	Leukocyte Growth Factor [EPC]	Granulocyte colony-stimulating factor receptor	2022-01-01
Tepezza	TEPROTUMUMAB	Horizon Therapeutics Ireland	marketed	Insulin-like Growth Factor-1 Receptor Inhibitor [EPC]	IGF-1R	2020-01-01
Oxervate	CENEGERMIN	Dompe farmaceutici s.p.a.	marketed	Recombinant Human Nerve Growth Factor [EPC]	High affinity nerve growth factor receptor	2017-01-01
Lartruvo	OLARATUMAB	Eli Lilly	marketed	Platelet-derived Growth Factor Receptor alpha Antagonist	Platelet-derived growth factor receptor alpha	2016-01-01
Citomix	INTERFERON	Bayer Healthcare Pharms	marketed	Lymphocyte Growth Factor [EPC]		2015-01-01
Portrazza	NECITUMUMAB	Eli Lilly Co	marketed	Epidermal Growth Factor Receptor Antagonist [EPC]	Epidermal growth factor receptor	2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth factor class)

Chinese PLA General Hospital · 2 drugs in this class
Hyuk moon Kim · 2 drugs in this class
Centre Oscar Lambret · 1 drug in this class
Genzyme, a Sanofi Company · 1 drug in this class
SVS Institute of Dental Sciences · 1 drug in this class
Soligenix · 1 drug in this class
Xiamen Amoytop Biotech Co., Ltd. · 1 drug in this class
Adocia · 1 drug in this class
Zensun Sci. & Tech. Co., Ltd. · 1 drug in this class
Australasian Gastro-Intestinal Trials Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BioChaperone PDGF-BB — Competitive Intelligence Brief. https://druglandscape.com/ci/biochaperone-pdgf-bb. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing